MAPT and Alzheimer disease: In this regard, the National Institute on Aging-Alzheimer’s Association (NIA-AA) research criteria for AD were reviewed in 2018 to introduce Aβ (A), tau (T) and neurodegeneration (N) biomarkers, resulting in the AT(N) framework (Jack et al., 2018).